TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 10910540
Drug: Kayexalate resin
Normalized name: Benzoin resin
DrugBank: Benzoin resin (DB11222)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Kayexalate resin enema (n = 20); dose of Kayexalate was 1 gm/Kg body weight given rectally every four hours.
Study: 8584194
Drug: Caudal epidural
Normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caudal epidural analgesia with bupivacaine and morphine
Study: 8584194
Drug: Endovenous analgesia
Normalized name: Analgesic Balm GRX
Approvals — FDA: no, EMA: no, PMDA: no
Description: Endovenous analgesia with morphine boluses
Study: 6295422
Drug: sequential hemi-body
Approvals — FDA: no, EMA: no, PMDA: no
Description: sequential hemi-body irradiation (HBI)
Study: 6295422
Drug: 3-drug cyclic
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3-drug cyclic chemotherapy (CC)
Study: 31272528
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg memantine tablet formulation A
Study: 31272528
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg memantine tablet formulation B
Study: 15189492
Drug: NPH insulin
Normalized name: NPH Insulin, Human 300 UNT per 3 ML Prefilled Syringe
Approvals — FDA: no, EMA: no, PMDA: no
Description: NPH insulin (mean dose 0.33 +/- 0.15; range 0.09-0.66 units/kg/d) administered twice daily
Study: 8083823
Drug: Concomitant medications
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concomitant medications (average of 7.1 drugs per month for AIDS patients)
Study: 8083823
Drug: Concomitant medications
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concomitant medications (average of 3.1 drugs per month for ARC patients)
Study: 8083823
Drug: Concomitant medications
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concomitant medications (average of 2.7 drugs per month for asymptomatic patients)
Study: 8083823
Drug: Drug classes
Normalized name: VARIOUS DRUG CLASSES IN ATC
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug classes used
Study: 8083823
Drug: Prescription vs.
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prescription vs. over-the-counter drugs
Study: 8083823
Drug: Antivirals and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antivirals and vitamins consumption
Study: 8083823
Drug: Analgesics or
Normalized name: Medicated Pad or Tape
Approvals — FDA: no, EMA: no, PMDA: no
Description: Analgesics or antipyretics consumption
Study: 28985268
Drug: Intensive treatment
Normalized name: Head & Shoulders Intensive Treatment
DrugBank: Selenium Sulfide (DB00971)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intensive treatment (targeting SBP ≤ 120 mm Hg)
Study: 28985268
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment (targeting SBP ≤ 140 mm Hg)
Study: 8723308
Drug: Oral paroxetine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral paroxetine
Study: 1806624
Drug: mianserin (60‐90
Approvals — FDA: no, EMA: no, PMDA: no
Description: mianserin (60‐90 mg/day)
Study: 6308685
Drug: Captopril (CAP)
Normalized name: Captopril
DrugBank: Captopril (DB01197)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Captopril (CAP) 25 mg t.i.d. alone
Study: 6308685
Drug: Captopril (CAP)
Normalized name: Captopril
DrugBank: Captopril (DB01197)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Captopril (CAP) 25 mg t.i.d. with hydrochlorothiazide (HCTZ) 50 mg/day
Study: 6308685
Drug: Enalapril (ENA)
DrugBank: Enalapril (DB00584)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Enalapril (ENA) 5 or 10 mg/day
Study: 31988226
Drug: Referral to
Normalized name: Wong To Yick
Approvals — FDA: no, EMA: no, PMDA: no
Description: Referral to a commercial weight management programme plus stop smoking support (treatment group)
Study: 28403408
Drug: Lidocaine (i.v.‐bolus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lidocaine (i.v.‐bolus injection of 1.5 mg kg ‐1 at induction of anaesthesia, followed by an infusion of 1.5 mg kg ‐1 h ‐1 until six h after arrival at the post‐anaesthesia care unit)
Study: 25171056
Drug: 5,6-DMB supplement
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5,6-DMB supplement (1.5 g daily)
Study: 20953883
Drug: No supplement
Approvals — FDA: no, EMA: no, PMDA: no
Description: No supplement (Control)
Study: 23535096
Drug: Recombinant human
Normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Recombinant human C1 inhibitor (rhC1INH) 50-U/kg intravenous dose
Study: 23535096
Drug: Recombinant human
Normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Recombinant human C1 inhibitor (rhC1INH) repeated treatment
Study: 18829443
Drug: Korean hand
Normalized name: Korean ginseng root
DrugBank: Ginseng (DB01404)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Korean hand acupuncture therapy (HAT), 10 sessions
Study: 18829443
Drug: Hand moxibustion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hand moxibustion therapy (HMT), 10 sessions
Study: 16505133
Drug: 1.0 to
Normalized name: Pre Milk Iod 1.0 Topical Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.0 to 1.5 mg risperidone per day
Study: 14989395
Drug: Fexofenadine, 180
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fexofenadine, 180 mg once daily (10 PM)
Study: 14989395
Drug: Butterbur, 50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Butterbur, 50 mg twice daily (8 AM and 10 PM)
Study: 14989395
Drug: Montelukast, 10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Montelukast, 10 mg once daily (10 PM)
Study: 11381380
Drug: Arthrocentesis plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Arthrocentesis plus intra-articular injection of sodium hyaluronate (SH)
Study: 9216117
Drug: fenofibrate 100
Normalized name: fenofibrate 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: fenofibrate 100 mg tid
Study: 9216117
Drug: gemfibrozil 600
Normalized name: gemfibrozil 600 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: gemfibrozil 600 mg bid
Study: 3311548
Drug: Ibuprofen 400
Normalized name: ibuprofen 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibuprofen 400 mg plus Codeine 60 mg
Study: 3311548
Drug: Ibuprofen 200
Normalized name: ibuprofen 200 MG
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Ibuprofen 200 mg plus Codeine 30 mg
Study: 3311548
Drug: Codeine 60
Normalized name: codeine 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Codeine 60 mg alone
Study: 28443698
Drug: Maternal nutritional
Normalized name: Ocean Blue Nutritionals Omega-3 1450 Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maternal nutritional supplementation (MNS) 252 kcal/day daily up to 12 weeks postpartum and four breastfeeding education and support sessions
Study: 21910898
Drug: 2 g
Normalized name: Molds 2 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 g of plant sterol esters daily in liquid yoghurt for 24 months
Study: 17058629
Drug: Ezetimibe 10
Normalized name: ezetimibe 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ezetimibe 10 mg added to ongoing statin therapy
Study: 12965106
Drug: nateglinide 120
Normalized name: nateglinide 120 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: nateglinide 120 mg
Study: 10930201
Drug: Oral clonidine
Normalized name: Clonidine
DrugBank: Clonidine (DB00575)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral clonidine premedication (5 microg x kg(‐1) 90 min before surgery)
Study: 8737759
Drug: Nifedipine solution
Normalized name: Nifedipine
DrugBank: Nifedipine (DB01115)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nifedipine solution administered locally to the stomach
Study: 8737759
Drug: Nifedipine solution
Normalized name: Nifedipine
DrugBank: Nifedipine (DB01115)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nifedipine solution administered locally to the small intestine
Study: 8737759
Drug: Nifedipine solution
Normalized name: Nifedipine
DrugBank: Nifedipine (DB01115)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nifedipine solution administered locally to the colon (two sites)
Study: 8737759
Drug: Intravenous infusion
Normalized name: intravenous infusion pump accessory
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous infusion of nifedipine
Study: 20669317
Drug: Pramipexole ER
Normalized name: pramipexole Extended Release Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pramipexole ER once daily
Study: 20669317
Drug: Pramipexole IR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pramipexole IR three times daily
Study: 17432541
Drug: Application of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Application of antioxidant and mitochondrial stimulating cream and oral administration of antioxidants and phenylalanine
Study: 17432541
Drug: Application of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Application of antioxidant and mitochondrial stimulating cream
Study: 17432541
Drug: Placebo AF
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo AF (application of a placebo cream and oral administration of antioxidants and phenylalanine)
Study: 17432541
Drug: Without cream
Normalized name: threonine
DrugBank: Threonine (DB00156)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Without cream AF (oral administration of antioxidants and phenylalanine)
Study: 15710335
Drug: Conventional immunotherapy
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional immunotherapy (n=7)
Study: 15710335
Drug: Short-term immunotherapy
Normalized name: hydrogen peroxide
DrugBank: Hydrogen peroxide (DB11091)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Short-term immunotherapy (n=7)
Study: 11781125
Drug: Acupuncture (exact
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupuncture (exact dosage and duration not specified)
Study: 7554180
Drug: STAR (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: STAR (10 mg given intravenously over 30 minutes)
Study: 7554180
Drug: STAR (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: STAR (20 mg given intravenously over 30 minutes)
Study: 1983493
Drug: Postoperative treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Postoperative treatment modalities including ventilation, deflation of the interponate, and special dietary plan
Study: 20533765
Drug: Valacyclovir 250
Normalized name: valacyclovir 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Valacyclovir 250 mg
Study: 25147236
Drug: Valacyclovir 1000
Normalized name: valacyclovir 1000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Valacyclovir 1000 mg
Study: 19122337
Drug: Pranlukast 225
Normalized name: pranlukast
DrugBank: Pranlukast (DB01411)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: Pranlukast 225 mg single dose
Study: 19122337
Drug: Clarithromycin 200
Normalized name: Clarithromycin
DrugBank: Clarithromycin (DB01211)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Clarithromycin 200 mg twice daily for 7 days + Pranlukast 225 mg single dose on day 7
Study: 16618015
Drug: PRO 160/120
Approvals — FDA: no, EMA: no, PMDA: no
Description: PRO 160/120 (2 x 1 capsule/d)
Study: 16618015
Drug: Tamsulosin (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tamsulosin (1 x 0.4 mg/d)
Study: 15105283
Drug: B9340 (bradykinin
Approvals — FDA: no, EMA: no, PMDA: no
Description: B9340 (bradykinin receptor antagonist)
Study: 9699089
Drug: U40 regular
Normalized name: Insulina regular
DrugBank: Insulin human (DB00030)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: U40 regular insulin
Study: 9699089
Drug: U100 regular
Normalized name: Insulina regular
DrugBank: Insulin human (DB00030)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: U100 regular insulin at 8 degrees C
Study: 9699089
Drug: U100 regular
Normalized name: Insulina regular
DrugBank: Insulin human (DB00030)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: U100 regular insulin at 37 degrees C
Study: 2689469
Drug: Verapamil-SR 60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Verapamil-SR 60 mg
Study: 2689469
Drug: Verapamil-SR 120
Approvals — FDA: no, EMA: no, PMDA: no
Description: Verapamil-SR 120 mg
Study: 8134676
Drug: Propofol (1%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propofol (1% infusion at 6 mg/kg/h for 10 minutes, then 3 mg/kg/h)
Study: 8134676
Drug: Midazolam (0.3%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Midazolam (0.3% infusion with initial bolus of 0.06 mg/kg and infusion at 0.05 mg/kg/h)
Study: 30444838
Drug: Intensive treatment
Normalized name: Head & Shoulders Intensive Treatment
DrugBank: Selenium Sulfide (DB00971)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intensive treatment (target SBP < 120 mmHg)
Study: 30444838
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment (target SBP between 135 and 139 mmHg)
Study: 24125483
Drug: Spironolactone 50
Normalized name: spironolactone 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spironolactone 50 mg daily for 6 weeks
Study: 19106380
Drug: NPH/Lente insulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: NPH/Lente insulin
Study: 15133820
Drug: Naloxone (non-subtype-selective
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naloxone (non-subtype-selective opioid receptor antagonist)
Study: 7667832
Drug: Low-dose estrogen
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose estrogen (0.625 mg conjugated estrogens)
Study: 7667832
Drug: Oral contraceptives
Normalized name: VCF Contraceptive
DrugBank: Nonoxynol-9 (DB06804)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral contraceptives (30-50 micrograms ethinyl estradiol daily)
Study: 7667832
Drug: High-dose estrogen
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose estrogen (300 micrograms ethinyl estradiol daily)
Study: 2654329
Drug: C +
Normalized name: Probiotic + Colostrum
Approvals — FDA: no, EMA: no, PMDA: no
Description: C + M (methotrexate 50 mg/m2 on days 1 and 15 plus cisplatin 80 mg/m2 on day 2 every 4 weeks)
Study: 2654329
Drug: C (cisplatin
Approvals — FDA: no, EMA: no, PMDA: no
Description: C (cisplatin 80 mg/m2 on day 1 every 4 weeks)
Study: 28279941
Drug: Neoadjuvant chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoadjuvant chemotherapy + trastuzumab in HER2-positive cases
Study: 28279941
Drug: Neoadjuvant chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoadjuvant chemotherapy + celecoxib in HER2-negative cases
Study: 21671456
Drug: Nabiximols 10.8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nabiximols 10.8 mg
Study: 21671456
Drug: Nabiximols 21.6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nabiximols 21.6 mg
Study: 21671456
Drug: Nabiximols 43.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nabiximols 43.2 mg
Study: 11480500
Drug: Dietary antioxidants
Normalized name: antioxidant 119
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dietary antioxidants (400 IU vitamin E/500 mg vitamin C)
Study: 8049437
Drug: Standard or
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard or high-dose Ara-C together with daunorubicin and etoposide as induction chemotherapy
Study: 3288477
Drug: L-dopa (as
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-dopa (as Sinemet)
Study: 30131049
Drug: Treatment irrespective
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment irrespective of salt sensitivity and dosing regimen
Study: 27428108
Drug: Complementary Therapies
Normalized name: Theraplex Eczema Therapy
DrugBank: Colloidal oatmeal (DB11286)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Complementary Therapies for Labour and Birth (CTLB) protocol, which includes acupressure, relaxation, visualisation, breathing, massage, yoga techniques, and facilitated partner support, attended a two-day antenatal education programme plus standard care.
Study: 15679556
Drug: Supervised treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Supervised treatment with sulfadoxine/pyrimethamine and artesunate
Study: 15679556
Drug: Unsupervised treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Unsupervised treatment with sulfadoxine/pyrimethamine and artesunate
Study: 10589887
Drug: Daily trimethoprim-sulfamethoxazole
Normalized name: sulfamethoxazole / trimethoprim
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily trimethoprim-sulfamethoxazole (160 mg/800 mg)
Study: 10589887
Drug: Thrice-weekly trimethoprim-sulfamethoxazole
Normalized name: sulfamethoxazole / trimethoprim
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thrice-weekly trimethoprim-sulfamethoxazole (160 mg/800 mg)
Study: 7852106
Drug: Twice-daily radiation
Normalized name: clindamycin
DrugBank: Clindamycin (DB01190)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Twice-daily radiation therapy (RT) at 1.2 Gy BID (64.8 Gy, 72.0 Gy, 76.8 Gy, 81.6 Gy)
Study: 2045613
Drug: Atropine (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atropine (4 mg/ml) inhaled for 5 minutes
Study: 2045613
Drug: Fenoterol (0.4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fenoterol (0.4 mg/ml) inhaled for 5 minutes
Study: 2045613
Drug: Aminophylline (250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aminophylline (250 mg) intravenous injection
Study: 21646287
Drug: Phlebotomy therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phlebotomy therapy
Study: 6173993
Drug: Low-dose chloroquine
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose chloroquine treatment
Study: 31953634
Drug: 40 mg
Normalized name: rutin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg pantoprazole per day for 3 months
Study: 31953634
Drug: No PPI
Normalized name: PPI-1040
DrugBank: PPI-1040 (DB17620)
Approvals — FDA: no, EMA: no, PMDA: no
Description: No PPI therapy
Study: 23767862
Drug: 400 mg
Normalized name: mesna 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mg of herbal blend twice daily
Study: 20730056
Drug: Milk fortified
Approvals — FDA: no, EMA: no, PMDA: no
Description: Milk fortified with 2.4 g/day of prebiotic oligosaccharide and 1.9x10(7) c.f.u/day of probiotic Bifidobacterium lactis HN019
Study: 3786334
Drug: 2 mg
Normalized name: iodine 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mg nasal nicotine solution (NNS)
Study: 3786334
Drug: 0.15 mg
Normalized name: iodine 0.15 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.15 mg nasal nicotine solution (NNS)
Study: 3786334
Drug: 2.5 mg
Normalized name: biotin 2.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.5 mg mecamylamine
Study: 3786334
Drug: Repeated dosing
Normalized name: eicosyl povidone (2 eicosyl branches-repeat)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Repeated dosing with 2 mg NNS hourly for six hours
Study: 21987535
Drug: Aliskiren 150
Normalized name: aliskiren 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aliskiren 150 mg/d for 7 days (aliskiren group, n = 10)
Study: 16293536
Drug: Single concentration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single concentration methacholine inhalation provocation test (SCIPT) with doses of 0.03-1.8 mg (maximal cumulated dose 3.6 mg)
Study: 16293536
Drug: Standard dosimeter
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard dosimeter method (SDM) with doses of 0.002-1.8 mg (maximal cumulative dose 3.5 mg)
Study: 9873842
Drug: Home treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Home treatment not available, less treatment in general
Study: 8721461
Drug: Heparin-coated circuits
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heparin-coated circuits (HC group, n = 9)
Study: 8721461
Drug: Heparin-coated circuits
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heparin-coated circuits (HC group)
Study: 1824527
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg of nifedipine
Study: 11806863
Drug: 40 mg
Normalized name: rutin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg of propranolol
Study: 1824527
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg of nifedipine and 40 mg of propranolol
Study: 6339379
Drug: Oral killed
Normalized name: Hongo Killer
DrugBank: Undecylenic acid (DB11117)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral killed polyvalent bacterial vaccine (3 courses over 2 months, each course containing 10^10 Haemophilus influenzae and 7 x 10^9 Staphylococcus aureus organisms)
Study: 6339379
Drug: Oral killed
Normalized name: Hongo Killer
DrugBank: Undecylenic acid (DB11117)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral killed polyvalent bacterial vaccine
Study: 30565181
Drug: Metformin hydrochloride
Normalized name: Metformin Hydrochloride
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Metformin hydrochloride oral solution (500 mg/5 mL)
Study: 30565181
Drug: Metformin hydrochloride
Normalized name: Metformin Hydrochloride
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Metformin hydrochloride tablets (500 mg)
Study: 28629886
Drug: Mindfulness and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mindfulness and Self‐Compassion training program (2.5 hours/week for 8 weeks, 75% attendance, 45 minutes daily practice)
Study: 18977579
Drug: Oxytocin 5IU
Normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oxytocin 5IU bolus and placebo infusion
Study: 18977579
Drug: Oxytocin 5IU
Normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oxytocin 5IU bolus and oxytocin 30IU infusion
Study: 18021388
Drug: Anti-GLURP-IgG antibodies
Normalized name: Anti-VEGF monoclonal antibody
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Anti-GLURP-IgG antibodies
Study: 11993625
Drug: Regular carbohydrate‐electrolyte
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regular carbohydrate‐electrolyte beverage (6.8% CHO, 18.7 mmol/L Na, 3.0 mmol/L K, 1,130 kJ/L)
Study: 11993625
Drug: Low kilojoule
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low kilojoule electrolyte beverage (1% CHO, 18.7 mmol/L Na, 3.0 mmol/L K, 170 kJ/L)
Study: 1679668
Drug: Roxatidine 150
Normalized name: roxatidine 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Roxatidine 150 mg nocte
Study: 6352883
Drug: Intensive conventional
Normalized name: Uricalm Intensive
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intensive conventional therapy (three or four daily injections of insulin)
Study: 29572761
Drug: Weekly administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Weekly administration of paclitaxel and carboplatin (W‐TC)
Study: 27456885
Drug: PLISSIT model
Approvals — FDA: no, EMA: no, PMDA: no
Description: PLISSIT model based sexual counseling (4 weekly sessions, 90-120 min each)
Study: 24131282
Drug: BG-12 240
Normalized name: isopropyl alcohol
DrugBank: Isopropyl alcohol (DB02325)
Approvals — FDA: no, EMA: no, PMDA: no
Description: BG-12 240 mg three times daily